Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIPnew in Cystic Fibrosis with Pseudomonas aeruginosa
NCT01069705Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label trial of tobramycin in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection, sponsored by Novartis. Primary endpoints: Number of Participants With Adverse Events at 169 days and Number of Participants With Serious Adverse Events at 199 days. Started Feb 2010; status: completed.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on NCT01069705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01069705.